Scynexis Inc (SCYX) Stock Price & Analysis
Scynexis Inc (SCYX) fell 0.84% to USD 5.3 as of September 8, 2026 at 10:55 UTC, according to Nexqual real-time market data.
SCYX last closed at USD 5.3; the session ranged USD 5.18–5.44 on volume of 55,499 shares. Market capitalization is —, with a 52-week range of USD 3.53–10.48 (NCM). Source: Nexqual, September 8, 2026 at 10:55 UTC.
Key Statistics (as of September 8, 2026 at 10:55 UTC)
| Price | USD 5.3 |
|---|---|
| Change | ▼ 0.84% (down) |
| Previous Close | USD 5.3 |
| Open | USD 5.3 |
| Day Range | USD 5.18 – 5.44 |
| 52-Week Range | USD 3.53 – 10.48 |
| Volume | 55,499 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (SCYX)
Nexqual's technical model rates SCYX "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 10:55 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 58.73 (neutral) |
| vs SMA50 | Above (USD 4.71) |
| MACD | 0.16 (positive) |
From Scynexis Inc's Latest SEC 10-K Filing (filed 2026-03-04)
Key Strengths & Strategy (as disclosed to the SEC)
- We are developing our proprietary antifungal platform "fungerps", a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a broad range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis , Coccidioides , Histoplasma and Blastomyces genera and most common mucorales species.
- A second generation fungerp SCY-247 is currently being evaluated in clinical trials and additional compounds from our proprietary fungerp platform, targeted to address significant unmet needs, are in earlier stages of development.
- Intellectual Property We strive to protect the proprietary technology that we believe is important to our business, including seeking and maintaining patents intended to cover our product candidates and compositions, and their methods of use and other inventions that are commercially important to the development of our business.
Partnerships
- GSK has reiterated its commitment to continued collaboration with us regarding other aspects of the GSK License Agreement, including with respect to the commercialization of BREXAFEMME for VVC and rVVC indications.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LPCN | Lipocine Inc. | USD 2.45 | ▲ 4.03% |
| CLRB | Cellectar Biosciences, Inc. | USD 2.37 | ▼ 2.47% |
| ALDX | Aldeyra Therapeutics, Inc. | USD 1.48 | ▼ 0.67% |
| FBIO | Fortress Biotech, Inc. | USD 2.72 | ▼ 0.37% |
| TENX | Tenax Therapeutics, Inc. | USD 1.94 | ▲ 4.86% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 10:55 UTC. This page is informational and not investment advice.